279AW, Senior Scientist / Scientist, Cancer Immunotherapy – T Cell Development

Job Code 279AW

Description

Fate Therapeutics is seeking a highly motivated stem cell biologist, preferably with hematopoietic and lymphocyte development experience, to join our rapidly growing off-the-shelf cancer immunotherapy team in the development of novel cell therapeutics. The successful candidate will provide scientific and technical expertise contributing to the development and characterization of novel immunotherapies from discovery stage through product development and translation. This individual will lead various initiative to identify next generation cancer immunotherapy strategies as well as play a key role in collaborating with top scientific laboratories and institutions. S/he will perform, optimize, and analyze experiments and data involving T cell differentiation from pluripotent stem cells, characterization, proliferation, survival, and function. In addition, this role will have the opportunity to provide subject matter expertise and direction to regulatory, process development, and clinical teams. This position is located at our corporate headquarters in San Diego, California and reports to a Scientific Leader within T-Cell Development.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 279AW.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.